Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

News

8/27/2019 Ranking of Russian Pharmaceutical Distributors (Q1 – Q2)

It is unlikely that by the end of this year the pharmaceutical wholesale will have seen any significant achievements or failures. As of yet, the market is only developing in terms of public procurement. The public procurement segment has always been a very specific area, with a limited circle of players and its own rules, which are also very vaguely worded. For example, that massive breakdown in trading due to difficulties in setting the initial maximum price of the contract.

8/20/2019 Database Update: Pharmaceutical Drug Import for Clinical Trials to Russia (June 2019)

Between January and June 2019, Russia imported 319.8 thousand units, 8.2 bln RUB worth of pharmaceuticals for clinical trials (CT) (free circulation prices), which is in physical terms (units) 15.8% lower and in monetary terms (rubles) 1.4% lower than that of the same period in 2018. While the negative dynamics in physical terms have been registered at least thrice since 2013, the negative dynamics in monetary terms have been registered for the first time.

8/16/2019 Ranking of Russian Pharmacy Chains (Q1 – Q2 2019)

By June 2019, the pharmaceutical drug inflation rates have reached a value of 6%, especially against the background of the results of the previous two years. The rising prices, given the decreasing incomes of the population, will obviously be unable to lead to higher demand, and, as a result, the dynamics of the retail and commercial market for the first half of 2019, after a short surge in the first quarter, returned to last year's values, which are closer to stagnation than to growth (+2.4%).

8/15/2019 Database Update: API Import to Russia (June 2019)

Between January and June 2019, Russia imported 56.4 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms (rubles) 21% higher than that of the same period in 2018. In physical terms, Russia imported 5.8 thousand tons of APIs, and the dynamics are +6.1%, if calculated in kilos. 96.6% of the API import accounts for pharmacopoeial APIs.

8/9/2019 Database Update: Import of Veterinary Drugs, Feed Supplements, and Veterinary APIs to Russia (June 2019)

Between January and June 2019, Russia imported 31.9 bln RUB worth of veterinary products (free circulation prices), which is in monetary terms (rubles) only 0.1% higher than that of the same period in 2018. The dynamics are due to a decrease of the import of feed supplements in monetary terms, -8.2%. However, the import of feed supplements still amounts to as much as 16.8 bln RUB. The dynamics of the import of veterinary drugs in monetary terms are +10.4%, with over 13.8 bln RUB. The dynamics of the import of veterinary APIs are as high as +22%, with nearly 1.3 bln RUB.

8/8/2019 Database Update: Pharmaceutical Drug Import to Russia (June 2019)

Between January and June 2019, Russia imported 274.4 bln RUB worth of ready-made pharmaceuticals (free circulation prices), which is in monetary terms (rubles) 11.3% higher than that of the same period in 2018. The dynamics of the in-bull import in monetary terms are +2.2%, with 53.8 bln RUB.

7/25/2019 Database Update: Pharmaceutical Drug Production in Russia (June 2019)

Between January and June 2019, Russia produced 186.8 bln RUB worth of pharmaceutical drugs (manufacturers’ dispatch prices, VAT included), which is monetary terms (rubles) 18.8% higher than that of the same period in 2018. In physical terms, the dynamics are only +1.3% in units and +1.2% in minimum dosage units (MDU). The total volume of production for the period is around 2.1 bln units or 35.2 bln MDUs.

7/16/2019 Volume and Dynamics of Import of Ready-Made Pharmaceutical Drugs to Uzbekistan (2017 – 2018)

In 2018, Uzbekistan imported nearly 50 bln RUB worth of ready-made pharmaceuticals (CIP prices), which is in monetary terms (RUB) 3.9% higher than that in 2017. Despite the relatively low dynamics in monetary terms, the dynamics in physical terms are surprisingly high, +18%, and that was not due to changes in dosage forms. If calculated in minimum dosage units (MDU), the dynamics are +22.4%.

7/5/2019 Predicted Amounts of Additional VAT for Feed Supplement Importers to Russia (2016 – 2018, Q1 2019)

In early June, the media reported possible increase in meat prices in Russia due to feed supplement (FS) importers being charged additional VAT on top of the preferential tax rate of 10%. Until April 1 2019, most FS importers were charged the usual rate of 20% (18% until January 2019), while nearly 20% of FS import enjoyed the preferential rate of 10% in 2018. In 2016, it was around 25%, but it began rapidly decreasing in Q1 2019, when the Federal Customs Service, followed by the Ministry of Finance, toughened the preferential rate requirements.

7/2/2019 Pharmaceutical Drug and API Import from Georgia to Russia

In 2018, Russia imported 774.4 mln RUB worth of pharmaceuticals, which is in monetary terms (rubles) 8.7% higher than that of 2017, and 23.1 mln rub worth of APIs, which is monetary terms nearly 44% higher than that of 2017. The dynamics for the first three months of 2019 are even more impressive, with a 3.1 times increase for ready-made pharmaceuticals and a 3 times increase for APIs. However, this is due to lower importing activity in 2017.